REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design
Authors
Seckl, M.Ghorani, E.
Quartagno, M.
Blackhall, Fiona H
Gilbert, D. C.
O'Brien, M. E. R.
Ottensmeier, C. H. H.
Pizzo, E.
Spicer, J. F.
Williams, A.
Badman, P. D.
Parmar, M. K. B.
Affiliation
Imperial College London, LondonIssue Date
2023
Metadata
Show full item recordCitation
Seckl M, Ghorani E, Quartagno M, Blackhall FH, Gilbert DC, O'Brien MER, et al. REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005494.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2023.41.16_suppl.TPS9145Additional Links
https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.TPS9145Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2023.41.16_suppl.TPS9145